Although their clinical significance remains to be better determined, these findings do confirm that a substantial subgroup of patients with EGFRM+ NSCLC harbor some tumor cells with T790M co-mutation already before EGFR-TKI treatment. The gene discussed is EGFR; the disease is neoplasm.